William P. Harris, MD

William P. Harris, MD

Associate Member
Clinical Research Division


  • BS: Brown University, Providence, RI
  • MD: Columbia University, New York, NY
  • Residency: University of Washington, Seattle, WA
  • Fellowship: UWMC and Fred Hutchinson Cancer Research Center, Seattle, WA
  • Other notable training: Post-sophomore Fellowship in Pathology, University of Minnesota Medical Center

Research Focus

Dr. Harris is involved in several ongoing investigations of new therapeutics for the treatment of gastrointestinal malignancies.  His main current focus of investigation involves the study of new drugs such as targeted therapy and/or immunotherapy, the study of novel combinations of drugs, or local interventions in combination with experimental drug therapies for the treatment of hepatocellular carcinoma and biliary tract cancers (including cholangiocarcinoma).  These trials include Phase I-III trials.  Additional areas of focus include data analysis of outcomes after localized or systemic therapy for gastrointestinal malignancies, as well as identification of new treatments for fibrolamellar hepatocellular carcinoma, a rare disease affecting children and young adults.  

Clinical Expertise

Gastrointestinal cancers including liver, bile duct, pancreas, colon, rectal, anal, gastric, esophageal, and neuroendocrine tumors.


  • Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler AL, Harris WP. Journal of Clinical Interventional Radiology ISVIR: Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. Jul 2014 Volume 25(7):1067-1073
  • Riehle KJ, Yeh MM, Yu JJ, Kenerson HL, Harris WP, Park JO, Yeung RS. Modern Pathology: mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. Jan 2015 Volume 28(1):103-110
  • McCormick KA, Menon MP, Harris WP. "Hepatocellular carcinoma. Global perspectives on cancer: incidence, care and experience (A4002C)" a Praeger imprint. 2015
  • Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pschevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE. Clinical Cancer Research: Phase 1b study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Jun 2016 Volume 22(12):2848-2854
  • Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, Kwan S, Vaidya S, Monsky WL, Park JO, Bhattarcharya R, Hippe DS, Harris WP. Journal of Vascular and Interventional Radiology: Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. Jun 2017 Volume 28(6):777-785
  • Wong KM, Horton KJ, Coveler AL, Hingorani SR, Harris WP. Current Oncology Reports: Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20). Jul 2017 Volume 19(7):47
  • Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. Journal of Clinical Oncology: HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. Feb 2018 Volume 36(4):359-366
  • Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J. Lancet Oncology: Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomized, placebo-controlled study. May 2018 Volume 19(5):682-693
  • Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT. Annals of Oncology: Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Jun 2018 Volume 29(6) 1402-1408

Related News

William P. Harris, MD

Contact Information

(206) 606-6856
(206) 606-2042
Additional contact

Mail Stop: D5-310